Extracorporeal Magnetotransduction Therapy (EMTT): STORZ MEDICAL’s MAGNETOLITH receives 510(k) clearance from the FDA

On 3 May 2021, STORZ MEDICAL received the 510(k) clearance for the MAGNETOLITH^_® from the U.S. Food and Drug Administration (FDA). The therapy device is now cleared in the USA (as a class II medical device) for the following indications:

• Relaxation of muscle spasms
• Prevention or retardation of disuse atrophy
• Increase local blood circulation
• Muscle re-education
• Immediate post-surgical stimulation of calf muscles to prevent venous thrombosis
• Maintaining or increasing range of motion

»Extracorporeal Magnetotransduction Therapy (EMTT^®) with the MAGNETOLITH^® is an excellent addition to our shock wave portfolio on the US market. We already have well over 100 device orders,« says a delighted Alessandro Saccucci, STORZ MEDICAL’s Sales Director. »The 510(k) clearance opens up promising growth opportunities with a signal effect for other countries as well.«

EMTT^® differs from general forms of magnetic field therapy or PEMF due to the high oscillation frequency of 100 – 300 kHz. This property enables a high penetration depth and opens up a large range of indications. Treatment with the MAGNETOLITH^® requires little effort, is non-invasive and comfortable for the patient. . One treatment session lasts between 5 and 20 minutes, 6 to 8 sessions are required depending on the indication.